1. Home
  2. EML vs COYA Comparison

EML vs COYA Comparison

Compare EML & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastern Company (The)

EML

Eastern Company (The)

HOLD

Current Price

$20.51

Market Cap

119.2M

ML Signal

HOLD

Logo Coya Therapeutics Inc.

COYA

Coya Therapeutics Inc.

HOLD

Current Price

$4.47

Market Cap

126.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EML
COYA
Founded
1858
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.2M
126.6M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
EML
COYA
Price
$20.51
$4.47
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$15.80
AVG Volume (30 Days)
15.9K
101.5K
Earning Date
06-22-2026
01-01-0001
Dividend Yield
2.10%
N/A
EPS Growth
185.40
N/A
EPS
1.17
N/A
Revenue
$248,970,345.00
$3,554,061.00
Revenue This Year
$19.05
$69.95
Revenue Next Year
N/A
N/A
P/E Ratio
$17.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.61
$3.94
52 Week High
$26.78
$7.75

Technical Indicators

Market Signals
Indicator
EML
COYA
Relative Strength Index (RSI) 65.31 41.31
Support Level $17.96 $4.50
Resistance Level $20.93 $5.21
Average True Range (ATR) 0.66 0.27
MACD 0.26 -0.03
Stochastic Oscillator 77.30 22.00

Price Performance

Historical Comparison
EML
COYA

About EML Eastern Company (The)

The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.

About COYA Coya Therapeutics Inc.

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Share on Social Networks: